PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
-4.31%
Cost reduction while RVPH shows 0.00% growth. Joel Greenblatt would examine competitive advantage.
4.31%
Growth of 4.31% while RVPH shows flat gross profit. Bruce Berkowitz would examine quality advantage.
No Data
No Data available this quarter, please select a different quarter.
4.88%
R&D growth while RVPH reduces spending. John Neff would investigate strategic advantage.
-40.17%
Both companies reducing G&A. Martin Whitman would check industry cost trends.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.25%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-8.25%
Both companies reducing total costs. Martin Whitman would check industry trends.
No Data
No Data available this quarter, please select a different quarter.
-4.31%
Both companies reducing D&A. Martin Whitman would check industry patterns.
8.31%
EBITDA growth 50-75% of RVPH's 11.33%. Martin Whitman would scrutinize operations.
No Data
No Data available this quarter, please select a different quarter.
8.25%
Operating income growth 50-75% of RVPH's 11.28%. Martin Whitman would scrutinize operations.
No Data
No Data available this quarter, please select a different quarter.
133.19%
Similar other expenses growth to RVPH's 131.63%. Walter Schloss would investigate industry patterns.
12.55%
Similar pre-tax income growth to RVPH's 15.74%. Walter Schloss would investigate industry trends.
No Data
No Data available this quarter, please select a different quarter.
175.66%
Tax expense growth above 1.5x RVPH's 88.27%. Michael Burry would check for concerning trends.
12.55%
Similar net income growth to RVPH's 15.69%. Walter Schloss would investigate industry trends.
No Data
No Data available this quarter, please select a different quarter.
15.52%
Similar EPS growth to RVPH's 20.00%. Walter Schloss would investigate industry trends.
15.52%
Similar diluted EPS growth to RVPH's 20.00%. Walter Schloss would investigate industry trends.
3.21%
Share count reduction exceeding 1.5x RVPH's 7.13%. David Dodd would verify capital allocation.
3.21%
Diluted share reduction exceeding 1.5x RVPH's 7.13%. David Dodd would verify capital allocation.